Health Times of Rhode Island: Press Releases

Browse our comprehensive archive of press releases by date.
Select a specific day to access all press releases published on Health Times of Rhode Island.

Press releases published on August 4, 2026

Aug. 4, 2026

Cirrus Therapeutics Strengthens Its Position as a Next-Generation Global Ocular Immunology Leader with Singapore Eye Research Institute (SERI) Collaboration and Additional Financing

Indeterminate GlobeNewswire

Aug. 4, 2026

SHY Therapeutics Announces the First Patient Has Been Dosed in Phase 1 Clinical Trial Evaluating SHY-ONC6, a Novel, Oral Proteasome Inhibitor for the Treatment of Solid Tumors

Indeterminate GlobeNewswire

Aug. 4, 2026

Galectin Therapeutics Announces Conversion of $105.8 Million in Debt to Equity, Significantly Strengthening Balance Sheet

Indeterminate GlobeNewswire

Aug. 4, 2026

Teleflex Medical OEM Launches as INGENYX to Empower Tomorrow’s MedTech Innovators

Indeterminate GlobeNewswire

Aug. 4, 2026

Beyond Air Schedules Conference Call to Discuss Financial Results for the Quarter Ended June 30, 2026

Indeterminate GlobeNewswire

Aug. 4, 2026

Rani Therapeutics Appoints Michelle Gilson to Board of Directors

Indeterminate GlobeNewswire

Aug. 4, 2026

Exagen Inc. Reports Second Quarter 2026 Financial Results

Indeterminate GlobeNewswire

Aug. 4, 2026

Rein Therapeutics Announces Publication of Landmark LTI-03 Clinical Data in Nature Communications

Indeterminate GlobeNewswire

Aug. 4, 2026

Medvantx Opens New Louisville Facility Expanding Capacity for Pharmacy Fulfillment

Indeterminate GlobeNewswire

Aug. 4, 2026

YD Bio Highlights Peer-Reviewed Publication on New Computational Framework for Keratoconus Research

Indeterminate GlobeNewswire

Aug. 4, 2026

Medela Marks World Breastfeeding Week with Research Contribution and Educational Campaign

Indeterminate GlobeNewswire

Aug. 4, 2026

Nuvectis Pharma Reports Second Quarter 2026 Financial Results and Business Highlights

Indeterminate GlobeNewswire

Aug. 4, 2026

Leads Biolabs Announces Partner Oblenio Bio Doses First Patients in Phase 1a Trial of LBL‑051 for Refractory Autoimmune Diseases

Indeterminate GlobeNewswire

Aug. 4, 2026

Zevra Therapeutics to Present at the Canaccord Genuity Annual Growth Conference

Indeterminate GlobeNewswire

Aug. 4, 2026

CMS Grants New Technology Add-On Payment (NTAP) Status for ZEVASKYN®

Indeterminate GlobeNewswire

Aug. 4, 2026

Palvella Therapeutics Reports Second Quarter 2026 Financial Results and Provides Corporate Update

Indeterminate GlobeNewswire

Aug. 4, 2026

Harmony Biosciences Announces Record Q2 2026 Revenue and Shares Initial Clinical Data for Its Orexin-2 Agonist BP-205 Reinforcing Potential Best-in-Class Profile

Indeterminate GlobeNewswire

Aug. 4, 2026

Dyadic Expands Commercial Non-Animal Dairy Pipeline Through New Strategic Development Agreement

Indeterminate GlobeNewswire

Aug. 4, 2026

Invivyd Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) 

Indeterminate GlobeNewswire

Aug. 4, 2026

Rhythm Pharmaceuticals Reports Second Quarter 2026 Financial Results and Business Update

Indeterminate GlobeNewswire